 Connection
Ty Kiser to Fibrinolytic Agents
This is a "connection" page, showing publications Ty Kiser has written about Fibrinolytic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.161 |
|
|
|
-
Kiser TH, Burnham EL, Clark B, Ho PM, Allen RR, Moss M, Vandivier RW. Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism. Crit Care Med. 2018 10; 46(10):1617-1625.
Score: 0.530
-
Beyer JT, Schoeppler KE, Zanotti G, Weiss GM, Mueller SW, MacLaren R, Fish DN, Kiser TH. Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study. Clin Appl Thromb Hemost. 2018 Jan; 24(1):145-150.
Score: 0.460
-
Babilonia KM, Golightly LK, Gutman JA, Hassell KL, Kaiser JN, Kiser TH, Klem PM, Trujillo TC. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost. 2014 Nov; 20(8):799-806.
Score: 0.099
-
Owen PS, Tan EC, Kiser TH, Fish DN, MacLaren R. Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). Am J Health Syst Pharm. 2010 Jan 15; 67(2):136-43.
Score: 0.072
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|